It is a link for moving within the page.

  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2011
  5. In-vitro Diagnostic Kit, WT1 mRNA Assay Kit 'Otsuka' Received Regulatory Approval for Additional Purpose of Use with Myelodysplastic Syndromes

February 16, 2011

Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals

In-vitro Diagnostic Kit, WT1 mRNA Assay Kit 'Otsuka' Received Regulatory Approval for Additional Purpose of Use with Myelodysplastic Syndromes

Otsuka Pharmaceutical Co., Ltd. (Head Office: Chiyoda-ku, Tokyo, Japan; President: Taro Iwamoto) today announced that it received regulatory approval for the additional purpose of use with myelodysplastic syndrome, for its WT1 mRNA Assay Kit "Otsuka," an in-vitro diagnostic kit, in Japan on February 14, 2011. WT1 mRNA Assay Kit "Otsuka" is already approved as a MRD monitoring marker for acute myeloid leukemia in Japan.


Information in this news release was current as of the original release date.

Latest Pharmaceutical Business related News Releases

Most Recent Releases